We have used a monoclonal antibody-based ELISA for plasma prothrombin fragment 1.2 (Fl .2) to establish appropriate sample collection and storage conditionsfor this biomarker of thrombin generation. Fl IN) , and purified F1.2 was prepared by cleavage of prothrombin by factor Xa as previously described (10). Thromboplastin (Simplastin Excel) and the Simplastin Auto-
plasma from a different healthy donor collected into heparin, citrate, or EDTA, and a heparinized plasma pool were also treated with factor Xa, thrombin, both, or saline, then assayed as described above.
In another experiment, factor Xa (90 nmol/L final) or saline was added to heparinized plasma samples containing 12%, 30%, 45%, 60%, 85%, or 100% of the normal concentration of antithrombin Ill (plasma prepared as described above). Dilution of plasma by volume additions was <2%. 
Results

Selection and in vitro evaluation
of choice anticoagulant. Since factor Xa and thrombin formed during or after blood collection could potentially modify plasma F1.2 concentrations, the effect of these proteases on plasma F1.2 was evaluated in plasma prepared from blood collected from a healthy donor into either citrate, ACD, EDTA, oxalate, or heparin (Fig. 1) Effects of platelet concentration and aggregation on plasma F1.2 recovery. The effect of using platelet-rich vs platelet-poor plasma for F1.2 measurements in heparinized plasma was evaluated.
In platelet-rich plasma, the mean (±SD) recoveries of 2.5 nmol/L and 25 nmol/L F1.2 were 106 ± 16% (n = 3) and 99 ± 2% (n = 3), respectively.
These values are similar to that previously reported (10) for F1.2 recovery in platelet-poor plasma containing 0. 
